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Abstract: A key question confronting computational chemists concerns the preferable ligand ge-
ometry that fits complementarily into the receptor pocket. Typically, the postulated ‘bioactive’ 3D
ligand conformation is constructed as a ‘sophisticated guess’ (unnecessarily geometry-optimized)
mirroring the pharmacophore hypothesis—sometimes based on an erroneous prerequisite. Hence,
4D-QSAR scheme and its ‘dialects’ have been practically implemented as higher level of model
abstraction that allows the examination of the multiple molecular conformation, orientation and
protonation representation, respectively. Nearly a quarter of a century has passed since the eminent
work of Hopfinger appeared on the stage; therefore the natural question occurs whether 4D-QSAR
approach is still appealing to the scientific community? With no intention to be comprehensive, a
review of the current state of art in the field of receptor-independent (RI) and receptor-dependent
(RD) 4D-QSAR methodology is provided with a brief examination of the ‘mainstream’ algorithms. In
fact, a myriad of 4D-QSAR methods have been implemented and applied practically for a diverse
range of molecules. It seems that, 4D-QSAR approach has been experiencing a promising renaissance
of interests that might be fuelled by the rising power of the graphics processing unit (GPU) clusters
applied to full-atom MD-based simulations of the protein-ligand complexes.
Keywords: 4D-QSAR; structure-based SAR; receptor-dependent models; 4D-derived descriptors
1. Introduction
Nearly a quarter of a century has passed since the eminent work of Hopfinger ap-
peared on the stage [1]; therefore a natural question arises: Is the 4D-QSAR approach still
attractive to computational chemists? A rational production/prediction of ADMET-tailored
properties (in other words finding a ‘sweet spot’) in the hit→lead→seed→drug cascade
is a challenging object of interest for contemporary chemistry, that necessitates at least
four German G’s: Glück (luck), Geld (money), Geschick (skill) and Geduld (patience)—the
rank order of which depends on the discovery project under scrutiny [2,3]. The intuitive
decision-making process of the potential drug nomination or ‘false positives’ eradication at
the pre-synthetic stage can be supported by computer-assisted molecular design (CAMD)
to minimize the probability of drugs late-attrition according to ‘fail-early fail cheaply’
concept [4]. In fact, a variety of in-silico methods has been proposed in order to transform
the compound topology/topography encoded within the symbolic/numeric representa-
tions into the property-based chemical space [5]. The methodical observation of structural
modifications and the corresponding response variations (e.g., biological activity) for a
congeneric series of molecules is fundamental for the multidimensional (mD) quantitative
structure-activity relationship (QSAR) modeling—the analysis of analogy and/or simi-
larity is a ‘gold standard’ in the computational chemistry [6]. Moving from the intricate
biological systems to physically unrealistic SAR-mediated models on the path ‘towards the
prediction paradise’ is usually a backbreaking task more regarded as ‘a triumph of hope
over experience’, especially for non-congeneric compounds [7]. As is known, the complex
nature of inter/intramolecular interactions engaged in the process of the host-guest for-
mation makes the optimization of the pharmacological response a resource/knowledge
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CPU-intense issue. Basically, the quantitative mapping of the empirical/theoretical prop-
erties/descriptors into the ADMET-friendly molecular potency can be dichotomized into
‘indirect’ (ligand-based) and ‘direct’ (structure-based) procedures, respectively [8]. Concep-
tually, the receptor-independent (RI) approach stems loosely from the similarity principle,
where steric/electronic/lipophilic-alike interchangeable substituents are bound to exert a
similar impact on the pharmacological profile (neighbor behaviors) [9,10]. In practice, the
‘reverse image’ of the hypothetical target binding geometry is generated for the ensemble of
structurally-related (bio)molecules in the form of pharmacophoric pattern [11,12]. In other
words, the pseudoreceptor mapping can specify a spatial (3D) distribution of molecular
features that are necessary, but not sufficient for biological activity. As a matter of fact, a
number of 3D-QSAR procedures have been practically implemented in the field of medic-
inal/computational chemistry using molecular interaction/energy field (e.g., CoMFA),
molecular surface/volume (e.g., CoMSA) descriptors, respectively [13,14]. Comparative
molecular field analysis (CoMFA) is a widespread method that allows to model the in-
fluence of molecular shape on steric (Lennard–Jones) and electrostatic (Coulomb) effects
engaged in the non-covalent ligand-receptor interactions. Roughly speaking, CoMFA
assumes that differences in binding affinities or biological activity for a set of structurally-
related compounds can be explained by the comparative investigation of 3D patterns
produced within the cubic mesh of points, which encompasses aligned molecules using the
selected probe atoms [15]. A number of alternative CoMFA-like protocols have appeared,
e.g., comparative molecular surface analysis (CoMSA) that implemented corrections in
the molecular shape description, superimposition rules as well as the predictive model
quality [16]. The fuzzification of the molecular shape representation with the compound
alignment improvement seems to be of special interest owing to a potentially preferable
characterization of the binding affinity to the corresponding receptor structure. Hence,
CoMSA replaces potential values calculated at single points by the mean potential val-
ues specified for surface sectors [17]. Obviously, the rough quantitative comparison of
the field-based and surface-related descriptors can provide more realistic picture of the
ligand-target recognition scenario; however a question about the underlying biological
reality remains still unanswered. From the perspective of ‘drug hunters’ the incorporation
of the receptor geometry seem reasonable since (bio)effector multifaceted interaction mode
(in Latin ‘ligare’ means ‘to tie’) is mediated by the corresponding spatial arrangement of
target atoms in the active interface [18,19]. The qualitative and/or quantitative rational-
ization of the drug-target binding forces in the receptor-dependent (RD) procedures can
be partially achieved using the site-directed molecular docking approach; however the
system binding evaluation is still questionable due to deficiency of truly selective scoring
functions [20]. Regrettably, there is no a priori ‘rule of thumb’ in a successful voyage or
exploration of ADMET-friendly property space; therefore the collaborative fusion of RI
and RD procedures is advisable in order to support the chemists’ intuition [21].
In the conventional QSAR methodology a molecular structure is encoded using a pool
of descriptors, usually representing a single instance with the fixed conformation, protona-
tion, stereoconfiguration, tautomeric form, etc. Obviously, a molecule is a dynamic object,
that can simultaneously change the form of existence or even might exist in many forms
at the same time in equilibrium—it is especially important for modeling the biological
response profile and/or receptor interaction modes since approximately 50% of marketed
drugs are chiral and 25% possess several tautomers, respectively [22]. Hence, the proper lig-
and preparation and descriptor-weighted specification is valid at the early stages of QSAR
modeling with the employment of different protonation states and tautomeric forms [23].
Unfortunately, the alignment problem is another ‘Achilles heel’ of SAR approach, especially
for conformationally flexible systems. In order to broaden the applicability of QSAR mod-
eling a range of superimposition-free methodologies have been proposed (e.g., CoMSiA,
CoMMA, WHIM) for non-congeneric series of compounds [24]. Common problems of the
multi-step QSAR modeling with the variable selection/elimination, model generation and
validation are introduced in Figure 1.
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Figure 1. The most common issues in multi-stage QSARs.
Typically, the postulated ‘bioactive’ 3D ligand conformation is constructed as a ‘sophis-
ticated guess’ (not necessarily geometry-optimized ones) mirroring the pharmacophore
hypothesis—sometimes based on an erroneous prerequisite. Unfortunately, the application
of alignment-independent descriptors does not address the issues of the proper conformer
selection; therefore 4D-QSAR scheme and its ‘dialects’ have been practically implemented
as higher level of a model abstraction that allows the investigation of the multiple molecu-
lar conformation, orientation and protonation representation, respectively [25–28]. As a
matter of fact, 4D-QSAR methodology diffused quickly into medicinal and computational
chemistry becoming a long-established in silico milestone in the field of the computer-aided
molecular design. A working definition of 4D-QSAR approach is ‘a set of procedures which
allows the construction of optimized dynamic spatial QSAR models, in the form of 3D
pharmacophores, which are dependent on conformation, alignment, and pharmacophore-
grouping’ [29,30]. In other words, 4D-QSAR can be regarded as a variant of molecular
similarity estimation in the Molecular Shape Analysis (MSA), where the substitution of the
‘explicit’ atom-based compound pattern with the ‘implicit’ cube-alike population generates
‘fuzzy’ molecular representation [31,32]. Roughly speaking, 4D-QSAR incorporates some
features of the classical mesh-based 3D-QSAR (e.g., CoMFA) as a function of molecular con-
formation, superimposition and compound fragmentation to produce a molecular shape
spectrum (MSS) [33,34]. As a matter of fact, many-fold molecule replications (conformers)
allow to increase the chance of mapping the proper receptor form; therefore 4D-QSAR
scheme seems to be more probabilistic in nature compared to 3D-QSAR approaches [35,36].
The ‘fuzzification’ of the molecular representation by the cubic occupancy frequency can be
optionally augmented using the target data in the receptor-mediated studies [37]. Briefly,
the multi-step 4D-QSAR procedure is illustrated in Figure 2.
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Figure 2. Multi-step 4D-QSAR procedure.
With no intention to be comprehensive, a review of the current state-of-the-art in the
field of receptor-independent and receptor-dependent 4D-QSAR methodology is provided
with a brief description of the ‘mainstream’ algorithms. In fact, a myriad of 4D-QSAR
methods (namely dialects) have been implemented (grid, neural, lattice, simplex, hybrid,
quasar) and applied practically for a diverse range of chemicals as reported so far.
4D-QSAR Scientometrics: From Ecstasy to Agony?
Two decades have passed from the moment 4D-QSAR first appeared on the stage;
however it is not clear what actually triggers an increasing interest in 4D-QSAR that fades
after some years?
In order to provide the current state-of-the-art an extensive database screening was
performed to identify hits, where phrase ‘4D QSAR’ was queried using title, abstract or
keywords in the papers published during the last two decades (from 1997 to 2021). In con-
sequence, some puzzling regularities with the fluctuations of interest (namely waves) con-
cerning 4D-QSAR approach were revealed during the exploration of a commercially/freely
accessible repositories including Scopus, Reaxys, PubMed and Web of Science databases,
respectively. Interestingly, the analysis of database hits in function of time shows an al-
ternating tendency of waxing and waning interest in the conformationally-related QSAR
modeling as illustrated in Figure 3.
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Figure 3. Trends in the number of publications, where ‘4D QSAR’ was queried in the paper’s title,
abstract or keyword from 1997 to 2021.
It seems natural to question what actually induced the growing interest in 4D-QSAR
that then diminished after some years? Obviously, the resulting repository data are highly
intercorrelated; however noticeable variations in the number of publications per year are
observed, probably due to different search protocols implemented in the database engines.
On the other hand, some general trends are common for all the investigated databases. Not
surprisingly, the initial ‘ecstasy’ is mirrored in the rapid growth of the 4D-related reports
at the beginning of new millennium. Unfortunately, in the next decade the slowdown
(‘plateaux’) in the number of published papers was observed (with an exception of year
2012) presumably owing to CPU-demanding calculations as well as the reached limits of
the ligand-based protocols. The promising renaissance of interests in the receptor-mediated
4D-QSAR has been recorded recently (see Figure 3) that might be fueled by the rising power
of the graphics processing unit (GPU) clusters applied to full-atom MD-based simulations
of protein-ligand complexes [38].
2. 4D-QSAR Dialects: Towards ‘Magic Bullet’
2.1. Grid 4D-QSAR Strategy
The conventional cell-based Hopfinger’s 4D-QSAR coding system employs an en-
semble of cubic shape-like descriptors that are calculated for the multiple molecule con-
formational/alignment states as the ‘fourth pseudo-dimension’ [39]. The enhancement
of the 3D approaches by considering the additional dimension has been successfully ap-
plied in molecular modeling for the search of the active conformation and orientation in
binding/active site of the conformationally flexible molecules [40–42].
The geometry-optimized molecules are used as the initial structures in order to pro-
duce the compound trajectory in the molecular dynamics simulations (MDs) with the
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generation of the conformational ensemble profile (CEP). The individual conformers are
superimposed on the most active (reference) molecule according to the active analogue
approach (AAA) hypothesis—the maximum common substructure (MCS) for compounds
should be chosen in the superimposition mode. Roughly speaking, the multiple alignment
rules offer a possible solution to a system that involves more than one binding mode or
a dependence on different regions of the ligand molecule—the alignment issue can be
regarded as a search and sample operation corresponding to the conformational profil-
ing [43–46]. Moreover, molecules can be divided into ‘functional pieces’ called interaction
pharmacophore elements (IPEs) that correspond to the types of ligand-receptor interac-
tions [47,48]. Subsequently, a series of molecules is placed in the lattice space and the
so-called grid cell occupancy descriptors (GCODs) are calculated using singular cubic cell
resolution set to 1, 2 and 0.5 Å, respectively [49,50].
The extension of classical GCODs, namely charge descriptors, were engaged in our
calculations with the absolute charge occupancy (Aq) for the specified IPE of compound c
calculated as follows:




Ot(c, i, j, k)× q/m (1)
where m is the number of the atoms of compound c that appear in the cell (i, j, k) at time t,
q/m is the mean value of partial atom charges present in some cells at time t, T is the time
in MDs, and N is the number of sampling MDs steps.
The joint (Jq) and self-charge occupancy (Sq) descriptors with the most active reference
compound R were specified as:




Ot(c, i, j, k) ∩Ot(R, i, j, k)× q/m (2)




{Ot(c, i, j, k)− [∑Tt=0 Ot(c, i, j, k) ∩Ot(R, i, j, k)]} × q/m (3)
Each superimposition generates a characteristic grid cell occupancy/charge distri-
bution for a specified molecular trajectory. The grid cells are unfolded into vectors with
molecules as objects (rows) and occupancy/charge variables as descriptors (columns). The
pool of the cell descriptors can be enhanced by the additional non-GCODs, for instance,
lipophilicity coefficients (clogP). The formed array is applied to approach the structure–
activity relationship with PLS method conjugated with the variable selection/elimination
procedures (e.g., UVE/IVE or GFA) in order to specify the preferred spatial property
distribution. In fact, the data reduction is applied to construct the minimal set of similar-
ity/diversity descriptors that approximate the essence of the host-guest interactions [51].
The postulated ‘active conformation’ of each molecule specified on the basis of the exten-
sive sampling of the conformational/alignment freedoms can serve as a ‘preprocessor’ for
a subsequent 3D-QSAR analysis (e.g., CoMFA), as shown in Figure 4.
Grid-based RI-4D-QSAR paradigm was successfully implemented for mapping the
3D-pharmacophore sites of drug targets, for instance, benzodiazepine GABAA receptor, My-
cobacterium tuberculosis monophosphate kinase (TMPKmt), HIV-1 integrase/protease/ re-
verse transcriptase, glycogen phosphorylase, dihydrofolate reductase, cytochrome P450, p38-
mitogen-activated protein kinase (p38-MAPK) or serotonin transporter (SERT) [40,42,45–47,49].
As a first case study, the training set of the substituted 2,4-diamino-5-benzylpyrimidine
inhibitors of E. coli dihydrofolate reductase (DHFR) was analyzed in 4D-QSAR due to
noticeable system conformational flexibility (DHFR-benzylpyrimidine inhibitors have two
principal torsion angle degrees of freedom) [1]. As a matter of fact, 4D-QSAR preferred the
optimized 3D-QSAR models which include GCODs associated with the ‘fixed’ parts of the
structures (see Figure 5)—grid cells near the 2-amino group of the pyrimidine ring were
specified as crucial to the compounds inhibitory profile.
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Figure 4. Workflow of receptor dependent (RD) and receptor independent (RI) cell/SOM-based
4D-QSAR strategies.
Figure 5. Flexible bonds in trimethoprim.
Depending on the alignment rules and conformational analogue flexibility 4D-QSAR
identified slight variations among the binding modes of molecules as differences in both the
location and/or occupancy values of the GCODs related to ‘constant’ chemical structures.
The single ‘active conformation’ was specified as the lowest-energy conformer state which
maximizes the predicted activity using the best 3D-QSAR model.
A distinct site-directed 4D-QSAR approach has been promoted recently, where the
resultant 3D-pharmacophore pattern is directly dependent upon the explicit geometry
of the binding/active pocket in order to capture the potential induced-fit phenomena,
especially for the conformationally flexible ligand analogues [52–55]. Practically, some
geometric and force-field restrains are imposed due to distance-dependent short-range
characteristics of the host-guest interactions; therefore receptor pruning is advisable to
scale down the protein/enzyme to manageable size that embraces the ‘lining’ of the
binding/active site [56]. The adopted spatial distribution of the ligand descriptor/property
space is mediated by the corresponding mapping of target electronic, steric or lipophilic
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patterns using the molecular docking procedure [57,58]. The CPU-intense MD calculations
(computational time and resource constraints) of the flexible ligand and partially rigid
target can provide insight into the potential mechanism of ligand-receptor interactions.
In practice, the cell-based RD-4D-QSAR procedure was applied in modeling of Rho-
associated protein kinase inhibitors, HIV-1 protease inhibitors, peptidemimetic inhibitors
of Trypanosoma cruzi trypanothione reductase (TR) or inhibitors of glycogen phosphorylase
(GPb). As a case example, RD-4D-QSAR models were constructed for a series of peptides
reversible inhibitors of Trypanosoma cruzi trypanothione reductase that was used in the
alignment step [56]. The enzyme model was derived from PDB crystal structure and the
receptor pruning was performed to limit the time and computational cost of the practical
RD-4D-QSAR analysis, respectively. The set of peptide–TR complexes was generated
followed the reference ligand bound orientation/conformation (pose) in the active site.
Subsequently, the conformational profile recorded from each peptide-TR MD sampling
was placed in a reference cell lattice. The GFA-optimized RD models showed to be not
only statistically meaningful, but also robust in terms of the external predictivity. The
‘active conformation’ of each peptide-TR complex was hypothesized regarding the model
performance and superimposition mode. Moreover, RD 4D-QSAR models also qualitatively
‘captured’ the valid regions of the TR receptor.
2.2. Neural 4D-QSAR Methodology
A neural formalism with the engagement of the self–organizing maps (SOMs) for gen-
eration of a fuzzy 4D–QSAR–like representation of the conformational space was proposed
as an alternative to the classical Hopfinger’s strategy, in namely SOM-4D-QSAR [59,60].
The adaptive and competitive Kohonen algorithm was used in order to produce planar
(2D) topographic maps, that represent the signals from chosen atoms of the molecular
trajectory (see Figure 4). As a matter of fact, a sphere specified in space by a singular
neuron corresponds to a particular unit cube in the conventional 4D-QSAR approach [61].
On the whole, the SOM–4D–QSAR cascade consists of the subsequent operational steps:
Step 1: Model building—specification of a spatial geometry for each molecule in the
analyzed ensemble. Practically, each of the 3D structures can start the conformational
sampling; however the initial geometry optimization is advisable.
Step 2: Superimposition—selection of the trial alignment. Basically, the trial superimpo-
sition is produced on the most active compound (AAA approach) with FIT procedure to
encompass the whole bonding topology in the maximal common structure (MCS).
Step 3: Interaction Pharmacophore Elements (IPE)—compounds are partitioned into
subsets of atoms acting a privileged role in the modeled phenomena, e.g., aromatic, hydro-
gen bond donors, hydrogen bond acceptors, polar positive/negative partial charge, and
unrestricted (all) atom type.
Step 4: Conformational Ensemble Profile (CEP)—the dynamic simulations of molecular
system are conducted for sampled conformers that are used in the subsequent comparative
analysis. The geometry–optimized models are employed in the initial step in order to
produce molecular trajectory and the partial atomic charges using the semi-empirical
methods (e.g., PM3 or AM1).
Step 5: Comparative SOM mapping—the spatial coordinates and partial atomic charges
are engaged as the input to form a 2D topographic map. In the course of training these
data are distributed among neurons resulting in the sum occupancy or mean charge maps.
Step 6: Variable reduction and model validation—a SAR relationship is modeled using the
PLS algorithm and LOO-CV conjugated with the IVE-PLS procedure for uninformative
variable elimination. External model validation is also monitored in order to measure the
predictive ability for the external test set. A vast sets of training/test samplings can be
monitored by the iterative Stochastic Model Validation (SMV) scheme [62].
Self-organizing RI 4D-QSAR approach was applied to generate a fuzzy ‘cubic-like’
representation of the conformational space for modeling dihydrofolate reductase inhibitors,
benzoic acids, azo dyes, steroids, HEPT analogues or the transdermal penetration effect
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(SKIN) and intestinal absorption enhancement (PAMPA). In order to address the issue of
the molecular flexibility the antiviral profile of substituted 1-[2-hydroxyethoxy)methyl]-6-
(phenylthio)-thymines (HEPT) analogues was investigated using 4D-QSAR method [60].
Generally, charge descriptors gave better models compared to the occupancy descriptors.
Our model also satisfied the ‘butterfly wing’ pattern properly indicating the interactions of
the side chains.
The structure-based variant of the SOM-4D-QSAR paradigm has been proposed for
modeling of dye-fiber affinity of anthraquinone derivatives [63]. The implemented RD
4D-QSAR approach focused mainly on the ability of mapping dye properties to verify
the concept of ‘tinctophore’ in dye chemistry. The neutral (protonated) and anionic (de-
protonated) forms of anthraquinone scaffold were examined in order to deal with the
uncertainty of the dye ionization state. The results are comparable to both the neutral and
anionic dye sets regardless of the occupancy and charge descriptors applied, respectively.
It is worth noting that the SOM-4D-QSAR behaves comparably to the cubic counterpart
which is observed in each training/test subset specification.
2.3. Lattice 4D-QSAR Approach
A new protocol, named Laboratorio de Quimiometria Teórica y Aplicada (LQTA), has
recently evolved from 3D/4D-QSAR methods. As a matter of fact, the lattice-related (L),
charge-based (Q), time-dependent (T) analysis (A) explores jointly the unique features of
CoMFA and 4D-QSAR using the intermolecular atom-probe interaction energies (Coulomb
and Lennard-Jones) at each grid point of the conformational space sampled in the molecu-
lar dynamic simulations [64]. Moreover, an evolution of receptor independent LQTA has
been proposed recently implementing the coupled combination of molecular docking and
dynamic simulation in order to predict/represent the kinetic state of compounds at target
binding site [65]. A simplified flowchart of the RI and RD-LQTA-4D-QSAR methodology is
provided in Figure 6. Firstly, the spatial ligand models are optimized using semi-empirical
or ab initio methods and the partial atomic charges are calculated at the (semi)quantum
modeling level (ChelpG). Hence, the topographic/topologic structural characteristic for
each molecule is specified using PRODRG on-line server or Topolbuild software as an input
to Gromacs trajectory generator [66]. Typically, the system is initially neutralized, mini-
mized and equilibrated and subsequently 500 ps trajectory space sampling is performed
to produce conformational ensemble profile (CEP) considering explicit aqueous medium
(SPC/E water model) [67]. The generated MDs frames are arbitrarily superimposed on the
reference molecule (ligand-based alignment) by matching the atomic positions—the root-
mean-square of the distances (RMSD) between the corresponding atom pairs is monitored.
The aligned CEPs are then enclosed in a hypothetical, regular 3D cell box with grid spacing
of 1 Å to calculate the energy-based interactions descriptors using LQTAgrid procedure.
The spatial map of the electrostatic (Columbic) and steric (Lennard-Jones) potentials
is generated using probe atoms, ions or functional groups (CH3+, H2O, CO2−, NH3+, etc.)
at the evenly distributed virtual lattice of points, where 3D-energy interaction descriptors
(IEDs) are computed at each cubic intersection according to formulas mentioned else-
where [68]. The multileveled data reduction procedure (digital filter) as a preprocessing
(block scaling) is then applied on the separated array of electrostatic and steric potentials
with a priori elimination of distant (cutoff = 30 kcal/mol), poorly distributed (variance
lower than 0.01 kcal/mol) and correlated (|R| < 0.3 or 0.2) mesh descriptors:
Est(x,y,z) or Eel(x,y,z) ≥ 30 → Est(x,y,z) or Eel(x,y,z) = 30 + log
(
Est(x,y,z) or Eel(x,y,z) − 30
)
(4)
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Figure 6. Flowchart of LQTA protocol.
The remaining descriptors are subjected to the ordered predictor selection (OPS), rear-
ranged according to the informative contribution and auto-scaled as well (mean-centered
and scaled to unity variance) prior to structure-activity model generation with the partial
least squares (PLS) [69]. In order to investigate the QSAR model robustness the extensive
validation is strongly advisable using the internal leave-several-out crossvalidation (LSO-
CV) or activity-randomization (Y-scrambling) and external training/test set population
analysis [70]. The model reliability and its applicability domain (AD) can be verified with
Golbraikh & Tropsha criterion and leverage approach, respectively [71].
Finally, the interpretable spatial distribution of interactions can be plotted as three-
dimensional color-coded contour maps (3D-pharmacophore) indicating the areas, where
steric hindrance and/or charged substituents increase or demolish the binding affinity.
Obviously, the incorporation of the target geometry into the LQTA protocol enables un-
biased ligand alignment in the receptor-based superimposition as well as the induced fit
simulation by exploration of mutual host-guest flexibilities [72]. Moreover, the Python
programming language and Django framework were employed to implement a web-based
and user-friendly graphical interface (called Web-4D-QSAR) integrating together the MDs
and LQTAgrid modules [73].
The computational details of lattice-based 4D-QSAR approach were presented for a
set of 4,5-dihydroxypyrimidine carboxamide derivatives acting as HIV-1 integrase (HIV-1
IN) inhibitors, benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one derivatives as Aurora
A kinase inhibitors, glycogen phosphorylase b inhibitors, MAP p38 kinase inhibitors,
β-diketoacid (DKA) derivatives, dipeptidyl peptidase-IV (DPP-IV) inhibitors or trypan-
othione reductase inhibitors. In order to introduce the potential of the receptor-dependent
LQTA-QSAR approach, an ensemble of phenothiazine derivatives that are specific com-
petitive Trypanosoma cruzi trypanothione reductase (TR) inhibitors were investigated [66].
The binding mode of the phenotiazine analogues was evaluated in a simulated induced fit
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approach. The ligands’ alignments were explored based upon both ligand and binding site
atoms, which is capable of providing unbiased CEP alignment. Based on the generated
models, the binding mode of the bent tricyclic inhibitors of TR was postulated as well.
2.4. SiRMS 4D-QSAR Protocol
A novel 4D-QSAR approach based on the simplex representation of molecular struc-
tures (SiRMS) has been implemented in order to overcome the superimposition ambiguity
for non-congeneric (heterogeneous) set of compounds—in this case the topological rep-
resentation is not a limitation [74]. Structural topography (topology and stereochemical
configuration) is encoded by a system of different simplexes defined as (un)bounded
‘tetraatomic fragments of fixed constitution, chirality and symmetry’ [75]. The overall
number m of all available simplexes for M-atomic structure is specified according to
m = M!/(M− 4)!× 4! formula. Generally, simplexes are ranked hierarchically (1D→4D),
where: 1D level is a combination of four atoms in the molecule; 2D level considers atomic
connectivity, atom type and bond nature; 3D lever regards the molecular stereochemistry
with chirality and symmetry; 4D level takes into account the probability of the particular
conformer realization in the set of conformers [76]. Each structural parameter Si in 4D-
QSAR modeling is computed by summing products of descriptors for each conformer Sik





Sik × Pk (5)
where N is the number of conformers under consideration, Sik is the i-th simplex descriptor
value for conformer k. The probability of conformer realization Pk is defined by its energy













where Ei and Ek are energies of conformations i and k, respectively.
The simplex-based 4D-QSAR operational cascade is briefly illustrated in Figure 7.
Typically, the generated, energetically-minimized 3D ligand models with the specified
properties (e.g., charges, lipophilicities) are used to sample the conformational space
of molecules (fourth dimension). Then, each conformer is fragmented into simplexes
taking into account the individual atomic characteristics, for instance, atom type, partial
charges, lipophilicity, refraction, electronegativity, hydrogen-bond nature (donor/acceptor),
attraction or repulsion potentials, etc. [77]. The stereochemical configuration of simplexes is
specified according to the modified Cahn-Ingold-Prelog (CIP) rules. Moreover, atoms can be
divided into definite discrete subgroups correspondingly to some arbitrary formed ‘bucket’
boundaries for the partial charges or lipophilic values. The property-related simplex-
retrieved representation of the conformational space for the ensemble of molecules arranged
in the array (independent variables) and biological activities (dependent parameter) are
then subjected to PLS analysis in order to establish QSAR relationship. The automatic
variable selection procedures based on iterative (e.g., stepwise) or evolutionary (e.g.,
genetic) algorithms can be employed [78]. Obviously, the final verification of QSAR models
using internal/external validation principles is a compulsory stage. Interestingly, a novel
simplex-related determination of the applicability domain has been proposed with a vector
that unifies two extreme points (active and inactive etalons) of the structural/property
space depicting the directional changes (from the inactive to the active one) of toxicity in the
variable space [79]. In order to simplify the interpretation of 4D simplex-based models the
individual atomic contribution Cj (positive or negative) can be color-coded according to the
accumulation of regression coefficients bj for all investigated atom-containing simplexes
M divided by the number of atoms in the particular simplex: Cj = 1/4 ∑Mi=1 bi [80]. In
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other words, the atoms or even molecular fragments that promote or interfere the modeled
activity can be identified as well as the postulated ‘productive’ (active) conformations can
be transferred to the subsequent 3D-QSAR analyses, respectively.
Figure 7. SiRMS protocol cascade.
On the whole, the absence of molecular superimposition, diverse variants of atom
differentiation and the explicit consideration of the stereochemical features in the confor-
mational space are the practical pros of SiRMS 4D-QSAR protocol.
A multileveled system of the simplex representation of molecular structure was imple-
mented in modeling of structure–anticancer/antiviral activity relationships for macrocyclic
pyridinophanes, an affinity analysis of substituted piperazines, anticancer activity of macro-
cyclic pyridinophane derivatives or cytotoxicity and antiherpetic activity of N,N’-(bis-5-
nitropyrimidyl)dispirotripiperazine derivatives. The operational details of simplex-based
protocol were comprehensively presented by the assessment of the substitution charac-
teristics of nitroaromatic compounds on the toxicity variations [80]. It was found that
an aromatic ring with nitro group(s) contributes positively to toxicity, even though this
contribution varies widely depending on the nature and number of other substituents. In
most cases, insertion of fluorine and hydroxyl groups into nitroaromatics increases toxicity,
whereas insertion of a methyl group has the opposite effect. Finally, some ‘toxicophore’
motifs were proposed using the hierarchical SiRMS protocol.
2.5. Hybrid 4D-QSAR Approach
The pharmacophore identification and bioactivity prediction using the electron confor-
mational-genetic algorithm (EC-GA) has been recently implemented in 4D-QSAR strat-
egy in order to detect the impact of stereoisomerism on the variations in the biological
responses [81]. A sophisticated hybrid combination of EC and GA rules incorporates
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conformational and superimposition freedom into the receptor-independent 4D-QSAR
protocol. The electronic and geometric/topological characteristics of n atoms are arranged
in the electron-conformational triangular matrix of congruity (ECMC) with n(n + 1)/2
elements constructed for each conformer. Comparing ECMS elements, a smaller number of
electron conformational submatrix of activity (ECSA) is specified within the given toler-
ances (a minimum one) in order to reveal the common pharmacophore pattern. The genetic
algorithm and non-linear least square regression (PLS) are engaged to produce and validate
the final 4D-QSAR models. The basic operational steps of the combined EC-GA approach
are presented in Figure 8. The ligand 3D structures are constructed and optimized using
the semi-empirical (PM3) or quantum chemical calculations (HF/6-311 G** level in the
aqueous medium) [82–84]. In order to generate the conformational ensemble profile for
the investigated series Monte Carlo (MC) randomized search simulations are conducted.
Each Boltzmann weighted conformer (densely populated) is characterized by triangular
ECMC matrix with the local atomic characteristic (e.g., partial charges, valence activities,
polarizabilities) on diagonal elements and the electron density distribution in 3D-space
for bonded (Wiberg’s index) or unbounded atoms (interatomic distances) as off-diagonal
elements, respectively. The lowest energy conformer of the most active molecule is cho-
sen as a reference compound and intercompared with the remaining ECMCs within a
predefined tolerance range to distinguish active from inactive compounds, respectively.
The resulting electron conformational submatrix of activity (ECSA) represents a specific
arrangement of functional groups in the active compounds (the pharmacophore pattern),
where Pα and αa demonstrate the probability of the pharmacophore occurrence in active
and low/non-active compounds, respectively [85,86]:
Pα = (n1 + 1)/(n1 + n3 + 2) (7)
αa = (n1 × n4 − n2 × n3)/
√
(m1 ×m2 ×m3 ×m4) (8)
where n1, n2 refer to the number of highly active and n3, n4 low active compounds bearing
and non-bearing pharmacophoric pattern; m1 and m2 specify the number of highly active
and weakly active molecules, whereas m3 = n1 + n3; m4 = n2 + n4. Roughly speaking, Pα
proves the possibility of the pharmacophore existence in the active compounds, while αa
reflects the deposit of both active/low active molecules.
Additionally, antipharmacophore shielding (APS) and auxiliary (AG) atoms/fragments
contribution to biological activity (negative or positive) can be introduced by means of the









where ajni are the parameters presenting the j-th type of the property impact in the i-th
conformation of the n-th molecule; N is the number of chosen parameters; constant κj
shows the relative weights of the parameters on the activity [87–89].
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Figure 8. EC-GA 4D-QSAR operational workflow.
Boltzmann weighted allotment of the compound’s conformer population to its activity
in a function of the molecular descriptors, energy and temperature is computed according









where δ is a Kronecker delta function of two variables:
δni =
{
0, Pha is absent
1, Pha is present
and An or Al correspond to activities of n-th and reference molecule l; mn or ml is the
number of conformations of n-th and reference molecule l; Eli or Eni represent the relative
energy of i-th conformation of n-th and reference molecule l; R is gas constant; T is temper-





approximation is a function of the ajni selection and the corresponding parameter weight
calculation (constant κj). The adjustable parameter κj is mathematically optimized using
a least square minimization of ∑n |Acalcn − A
exp
n |2 as a function of constant κj with the
computed and experimental activities specified for the training set.
Subsequently, the EMRE-retrieved pool of descriptors including the topological, spa-
tial or thermodynamic parameters is reduced using the stochastic, iterative and evolu-
tionary GA procedure of the selection→mutation→reproduction→fitness assessment to
eliminate uninformative variables [90–92]. Obviously, the selection of pertinent parameters
(optimization) is a challenging issue of the structure-activity modeling process. Finally, the
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performance (robustness and predictive power) of the generated EC-GA models should be
verified internally/externally using the training/test subset populations as recommended
by the Organization for Economic Co-operation and Development (OECD) principles and
Concordance Correlation Coefficient (CCC) criteria [93–95].
According to the available simulation data the EC-GA method seems to be a promis-
ing/effective tool for the comprehensive pharmacophore identification, relevant descriptor
specification and activity calculation, respectively [96]. In fact, the hybrid 4D-QSAR ap-
proach was successfully employed for pharmacophore identification of pyrazole pyridine
carboxylic acid derivatives, pyrrolo[2,1-c][1,4]benzodiazepines, N-morpholino triamino-
triazine derivatives, penicillins, 1,4-dihydropyridines, benzotriazines, HEPT analogues
or tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepinone (TIBO) derivatives. The ‘synergetic’
effect of the EC-GA conjugation (pharmacophore identification and bioactivity predic-
tion) was presented in modeling of antibacterial activity for the set of β-lactam antibiotics
(known as penicillin) [81]. According to the generated 4D-QSAR models with good de-
scriptive and predictive performance a new model was constructed and optimized using
only one conformer of each compound(3D-QSAR). It was also postulated that penicillin
activity was controlled by a pharmacophore containing seven atoms with certain electronic
and geometrical characteristics.
2.6. Quasar 4D-QSAR Approach
In order to address the shape-dependent complementarity pitfall at the stage of the
host-guest complex formation (e.g., the induced fit or H-bond flip-flop) the quasi-atomistic
receptor surface modeling approach (Quasar) has been proposed in the multidimensional-
QSAR as a conceptual ‘bridge’ between the RI and RD protocols, respectively [97]. The
manifestation/magnitude of the local induced fit (the ligand-mediated adaptation of
binding pocket to molecular topology/topography) or simulation of the H-bond flip-flop
particles (Ser, Thr, Tyr, Cys, His, Asn or Gln amino-acids acting simultaneously as HB
donors/acceptors due to a conformationally flexible H-bonding functions) are still challeng-
ing issues in the rational drug design. In consequence, the multiple ligand conformation,
orientation and protonation representation has been enhanced by an additional level of
model abstraction (degree of freedom)—the topology of the quasi-atomistic receptor surro-
gate [98,99]. The conceptual cascade of the Quasar 4D-QSAR is presented in Figure 9. An
averaged peptidic pseudoreceptor-surface family is constructed as a 3D ‘inner’ envelope
randomly populated with atomistic properties (e.g., hydrophobicity, partial charge, elec-
trostatic potential, H-bonding propensity), that surrounds the ligands of the training set
at the Van der Waals distance (radius 0.8 Å) [100]. Obviously, the hypothetical shape of
the receptor surface mirrors vaguely the steric nature of the binding site. In practice, the
ligand conformational space within this primordial envelope can be scanned with Monte
Carlo (MC) search algorithm. Next, the evolution of the initial family of receptor models is
performed by means of the genetic operators (crossover and random mutation) and the
estimation of relative free energies of ligand binding towards pseudoreceptor models is
conducted as well. A normalized Boltzmann distribution is used to evaluate the conformer
energy contribution to the total energy [101,102]. Finally, the scrambling tests are employed
to validate a family of receptor models using the training/test subsets of molecules. Prac-
tically, the binding data of training population are arbitrarily and recurrently scrambled
with respect to the true activities. Hence, based on the scramble-derived model the binding
energies for test set are foreseen—the higher prediction accuracy the worse model is due to
insensitivity towards the biological data [103].
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Figure 9. Quasi 4D-QSAR cascade.
The multiple-conformational (4D) Quasar approach provides an elegant way to esti-
mate the receptor-mediated interaction energies by populating receptor surface models
with atomic properties. In fact, the methodology allows for a subtle scaling of energetic con-
tributions of geometrically flexible molecules reducing the alignment bias. The adjustment
of an ‘averaged’ pseudoreceptor to an individual ligand geometry and the conformational
mobility of H-bond functionality can be simulated as well [104].
In order to constrain the superimposition bias in multi-conformational ligand repre-
sentation the Quasar concept was engaged to establish QSARs for neurokinin-1 receptor
antagonists and aryl hydrocarbon receptor antagonists (dibenzo-dioxins, dibenzofurans,
biphenyls, and polyaromatic hydrocarbons), dopamine β-hydroxylase inhibitors and aryl
hydrocarbon receptor antagonists or 5-HT2A receptor antagonists, respectively. More-
over, an automated quasi-4D-QSAR that mimicked the multi-way-PLS analyses to provide
predictive SAR models for highly flexible CXCR4 cyclic pentapeptide inhibitors was pro-
posed [97]. The bioactive conformer geometry and superimposition rule were specified
in the recurring loop of the activity-descriptor regression examination for the conformer
ensembles using two-way PLS protocol. The side chains of the cyclic pentapeptides were
indicated as the functional groups interacting with the CXCR4 receptor.
2.7. 4D-QSAR: Happy Stories
The detailed description of successful applications of RI/RD-4D-QSAR paradigm
is beyond the scope of this paper and it can be found elsewhere [105–115]. The rough
characterization of the scientific projects, where 4D-QSAR methodology was implemented
with the specification of the applied protocol, objects of interests and references is reported
in Table 1.
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Table 1. Brief characterization of 4D-QSAR protocols, research projects with references.
Methodology Protocol Research Subject References
Hopfinger’s
4D-QSAR
RD 4-hydroxy-5,6-dihydropyrone analogues as HIV-1 proteaseinhibitors Santos-Filho, O.A. et al. [29]
RI
norstatine derived inhibitors of HIV-1 protease based on the
3(S)-amino-2(S)-hydroxyl-
4-phenylbutanoic acid core (AHPBA)
Senese, C.L. et al. [28]
RD glucose inhibitors of glycogen phosphorylase b, GPb. Pan, D. et al. [30]
RD pyridinyl-imidazole and pyrimidinylimidazole inhibitors ofp38-mitogen-activated protein kinase (p38-MAPK) Romeiro, N.C. et al. [32]
RD C2-symmetric diol inhibitorsof HIV-1 protease(HOE/BAY-793 analogues) da Cunha, E.F.F. et al. [35]
RD 2-arylbenzothiophene derivatives Sodero, A.C.R. et al. [58]
RD glucose analogue inhibitors of glycogen phosphorylase (GPb) Pan, D. et al. [44]
RD peptides reversible inhibitors of Trypanosoma cruzitrypanothione reductase (TR) Silva da Rocha Pita, S. et al. [56]
RD
β-N-biaryl ether sulfonamide hydroxamate derivatives as
potent inhibitors
against matrix metalloproteinase subtype 9 (MMP-9)
Turra, K.M. et al. [88]
RI hydrazides Pasqualoto, K.F.M. et al. [34]
RI lamellarins against human hormone dependent T47D breastcancer cells Thipnate, P. et al. [33]
RI 5
′-thiourea-substituted
R-thymidine inhibitors Andrade, C.H. et al. [26]
RI 7-oxabicyclo[2.2.1]heptane oxazolethromboxane A2 (TXA2) receptor antagonists
Albuquerque, M.G. et al. [43]
RI antiarrhythmics agents Klein, C.D.P. et al. [55]
RI propofol (2,6-diisopropylphenol) analogues Krasowski, M.D. et al. [45]
RI benzothiophene analogs as dopamine D2 receptor inhibitors. Caldas, G.B. et al. [72]
RI tetrahydropyrimidine-2-one based inhibitors of HIV-1protease Senese, C.L. et al. [28]
RI azole antifungal P450 analogue inhibitors Liu, J. et al. [47]
RI glucose inhibitors of GPb. Hopfinger, A.J. et al. [11]
RI antifolates and pyrrolo[2,3-d]pyrimidines as antimalarialdihydrofolate reductase inhibitors Santos-Filho, O.A. et al. [49]
RI
benzylpyrimidine inhibitors of dihydrofolate reductase,
prostaglandin PGF2α antinidatory analogs,
dipyridodiazepinone inhibitors of HIV-1 reverse transcriptase
Hopfinger, A.J. et al. [1]
RI glucose analog inhibitors of glycogen phosphorylase Venkatarangan, P. et al. [40]
RI flavonoids Hong, X. et al. [36]




(TMPK) as potential antituberculosis agents
Andrade, C.H. et al. [25]
RI Leishmania donovani N-myristoyltransferase(NMT) inhibitors Santos-Garcia, L. et al. [112]
RI glucose analogue inhibitors of glycogenphosphorylase Hopfinger, A.J. et al. [40]
RI ecdysteroids and diacylhydrazines Hormann, R.E. et al. [105]
SOM
4D-QSAR
RD anthraquinone dyes Bak, A. et al. [62]
RI benzoic acids, azo dyes, and steroids Bak, A. et al. [59]
RI benzoic acids Polanski, J. et al. [6]
RI 1-[2-Hydroxyethoxy)methyl]-6-(phenylthio)-thymines (HEPT) Bak, A. et al. [60]
RI 2,4-diamino-5-benzylpyrimidine inhibitors Polanski, J. et al. [61]
RI cholic acid derivatives Bak, A. et al. [63]
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Table 1. Cont.
Methodology Protocol Research Subject References
LQTA
4D-QSAR
RI 3-pyrazolyl substituted coumarin derivatives Patil, R. et al. [70]
RD phenothiazine derivatives as trypanothione reductaseinhibitors Barbosa, E.G. et al. [66]
RD Gram-negative specific LpxC inhibitors Ghasemi, J.B. et al. [68]
RI glycogen phosphorylase b inhibitors and MAP p38 kinaseinhibitors Martins, J.P.A. et al. [64]
RI B-diketo acid derivatives as HIV-1 IN strand transferinhibitors (INSTI) de Melo, E.B. et al. [65]
RI benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one as as AuroraA kinase inhibitors Kanhed, A.M. et al.[67]
RI 4,5-dihydroxypyrimidine carboxamide derivatives Martins, J.P.A. et al. [73]
Simplex
4D-QSAR
RI macrocyclic pyridinophane analogues Kuzmin, V.E. et al. [74]
RI substituted piperazines Kuzmin, V.E. et al. [77]






Kuzmin, V.E. et al. [78]
Kuzmin, V.E. et al. [79]
Quasi
4D-QSAR
RI neurokinin-1 receptor antagonists Vedani, A. et al. [104]
RI
neurokinin-1 receptor antagonists and aryl hydrocarbon
receptor antagonists (dibenzodioxins, dibenzofurans,
biphenyls, and polyaromatic hydrocarbons)
Vedani, A. et al. [103]
RI dopamine β-hydroxylase inhibitors and aryl hydrocarbonreceptor antagonists Vedani, A. et al. [102]
RI phenylalkylamines, tryptamines, ergolines as 5-HT2Areceptor antagonists Streich, D. et al. [99]
RI CXCR4 cyclic pentapeptide inhibitors Bhonsle, J.B. et al. [97]
Hybrid
4D-QSAR
RI penicillin analogues Yanmaz, E. et al. [81]
RI tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepinone (TIBO)derivatives Akyüz, L. et al. [82]
RI 1-[(2-hydroxyethoxy)-methyl]-6-(phenylthio) thymine (HEPT)derivatives Akyüz, L. et al. [83]
RI benzotriazine derivativesas as sarcomainhibitors Sahin, K. et al. [85]
RI N-morpholinotriaminotriazine derivatives Saripinar, E. et al. [86]
RI ruthenium(II) arene complex derivatives Yavuz, S.C. et al. [87]
RI pyrrolo[2,1-c][1,4]benzodiazepinederivatives Özalp, A. et al. [89]
RI pyrazole pyridine carboxylic acid derivatives Tüzün, B. et al. [90]
RI alkynylphenoxyacetic acid analogues as CRTh2 (DP2)receptor antagonists Köprü, S. et al. [91]
RI phosphoinositide-3-kinase(PI3K) inhibitors Safavi-Sohi, R. et al. [98]
RI dipeptidyl boronic derivatives as proteasomeinhibitors Catalkaya, S. et al. [95]
3. 4D-QSAR: Twilight or Bright Future Perspective?
In summary, an outline of the current state-of-the-art in the area of ligand-based and
receptor-mediated 4D-QSAR is provided. The idea underlying 4D-QSAR assumes that a
molecule represented by several conformers is regarded as a particular case of the multiple
instance learning modeling—the Boltzmann average spatial distribution of the molecular
shape is a function of biological response variations. Obviously, the conformation-related
characteristics of the molecular flexibility and dynamic interactions with the target cannot
be captured by models trained on the chirality-unaware descriptors that are regarded
as a ‘bottleneck’ of the single-conformer 3D procedures. As a matter of fact, 4D-QSAR
approach has been experiencing a promising renewal of interest that might be fueled by
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the rising power of the graphics processing unit (GPU) clusters applied to the full-atom
MD-based simulations of protein-ligand complexes. For instance, Compute Unified Device
Architecture (CUDA) is a promising computing technology useful for support of general
purpose and parallel processing on graphics accelerators. Simply, the more computational
power the longer host-guest dynamic description (molecular trajectory). In practice, a
range of 4D-QSAR procedures (namely dialects) have been employed for various series
of compounds. On the other hand, new types of chirality-aware descriptors to encode
the conformational diversity, especially in the context of the multifaceted ligand-protein
(non-)covalent forces, are urgently needed. It seems, that after the years of stagnation in 4D-
QSAR development associated with CPU-limited emulation of the host-guest interactions,
the method has a brighter future ahead.
To the best of my knowledge, there is no other review that gathers the ‘mainstream’
algorithms of 4D-QSAR together.
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